This is a news story, published by IMR Press, that relates primarily to LLT news.
For more disease research news, you can click here:
more disease research newsFor more news from IMR Press, you can click here:
more news from IMR PressOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
statin treatment. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest density lipoprotein cholesterol news, atherosclerotic cardiovascular disease news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
StatinsIMR Press
•
70% Informative
Statins are the recommended first -line lipid-lowering therapy ( LLT ) for patients with primary hypercholesterolemia and established ASCVD.
The proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibody evolocumab has demonstrated significant LDL-C reductions.
VR Score
73
Informative language
76
Neutral language
31
Article tone
formal
Language
English
Language complexity
100
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links